Clinical trial
Dose Escalation Study to Evaluate the Safety and Antiviral Activity of Val-mCyd…
NCT00227435 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00227435 |
|---|---|
| Title | Dose Escalation Study to Evaluate the Safety and Antiviral Activity of Val-mCyd in Adults With Chronic Hepatitis C |
| Official title | A Phase I/II Double-Blind, Dose Escalation Study to Evaluate the Safety, Pharmacokinetics and Antiviral Activity of Val-mCyd (NM283) in Adults With Chronic Hepatitis C |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Chronic Hepatitis C |
| Intervention type | Drug |
| Interventions | val-mCyd |
| Start date | Feb 1, 2003 |
| Primary completion | Jul 1, 2004 |
| Completion | Jul 1, 2004 |
| First posted | Sep 28, 2005 |
| Last update posted | Apr 27, 2016 |
| Countries | United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: